Actelion Reports Positive Results in Macitentan Phase II Study

On average, patients were exposed to the study drug for more than 14 months, with a maximum exposure of 24.6 months. Macitentan was generally well tolerated in the patient population.

Switzerland's largest biotechnology company Actelion announced that its Phase II study of macitentan has demonstrated positive results in patients with idiopathic pulmonary fibrosis.

Macitentan, a tissue-targeting endothelin receptor antagonist, is expected to protect tissue from the damaging effect of elevated endothelin in the cardiovascular system.

The efficacy and safety of a 10mg dose of macitentan in patients with idiopathic pulmonary fibrosis was evaluated in a double-blind, randomised, placebo-controlled and multicentre study.

On average, patients were exposed to the study drug for more than 14 months, with a maximum exposure of 24.6 months.